Cargando…

A novel complement-fixing IgM antibody targeting GPC1 as a useful immunotherapeutic strategy for the treatment of pancreatic ductal adenocarcinoma

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers with a very low survival rate at 5 years. The use of chemotherapeutic agents results in only modest prolongation of survival and is generally associated with the occurrence of toxicity effects. Antibody-based i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Busato, Davide, Capolla, Sara, Durigutto, Paolo, Mossenta, Monica, Bozzer, Sara, Sblattero, Daniele, Macor, Paolo, Dal Bo, Michele, Toffoli, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685509/ https://www.ncbi.nlm.nih.gov/pubmed/38017492 http://dx.doi.org/10.1186/s12967-023-04745-9

Ejemplares similares

Nanoparticles-Based Oligonucleotides Delivery in Cancer: Role of Zebrafish as Animal Model
por: Bozzer, Sara, et al.
Publicado: (2021)

Biological Features of Nanoparticles: Protein Corona Formation and Interaction with the Immune System
por: Panico, Sonia, et al.
Publicado: (2022)

The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ductal Adenocarcinoma
por: Busato, Davide, et al.
Publicado: (2022)

Zebrafish: A Useful Animal Model for the Characterization of Drug-Loaded Polymeric NPs
por: Bozzer, Sara, et al.
Publicado: (2022)

Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies
por: Mossenta, Monica, et al.
Publicado: (2022)

Complement as a Biological Tool to Control Tumor Growth
por: Macor, Paolo, et al.
Publicado: (2018)

Prevention of Arthritis by Locally Synthesized Recombinant Antibody Neutralizing Complement Component C5
por: Durigutto, Paolo, et al.
Publicado: (2013)

Nanocarriers as a Delivery Platform for Anticancer Treatment: Biological Limits and Perspectives in B-Cell Malignancies
por: Bozzer, Sara, et al.
Publicado: (2022)

Targeted chitosan nanobubbles as a strategy to down-regulate microRNA-17 into B-cell lymphoma models
por: Capolla, Sara, et al.
Publicado: (2023)

Targeted Delivery of Neutralizing Anti-C5 Antibody to Renal Endothelium Prevents Complement-Dependent Tissue Damage
por: Durigutto, Paolo, et al.
Publicado: (2017)

Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies
por: Mossenta, Monica, et al.
Publicado: (2020)

The Dual Role of the Liver in Nanomedicine as an Actor in the Elimination of Nanostructures or a Therapeutic Target
por: Baboci, Lorena, et al.
Publicado: (2020)

Immunotherapeutic Targeting of GPC3 in Pediatric Solid Embryonal Tumors
por: Ortiz, Michael V., et al.
Publicado: (2019)

Multiple-Organ Complement Deposition on Vascular Endothelium in COVID-19 Patients
por: Macor, Paolo, et al.
Publicado: (2021)

Surface antibody changes protein corona both in human and mouse serum but not final opsonization and elimination of targeted polymeric nanoparticles
por: Capolla, Sara, et al.
Publicado: (2023)

Plasminogen activator-coated nanobubbles targeting cell-bound β2-glycoprotein I as a novel thrombus-specific thrombolytic strategy
por: Macor, Paolo, et al.
Publicado: (2022)

A Novel Epigenetic Machine Learning Model to Define Risk of Progression for Hepatocellular Carcinoma Patients
por: Bedon, Luca, et al.
Publicado: (2021)

New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma
por: Mossenta, Monica, et al.
Publicado: (2019)

A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy
por: Riccardi, Federico, et al.
Publicado: (2023)

IgM cleavage by Streptococcus suis reduces IgM bound to the bacterial surface and is a novel complement evasion mechanism
por: Rungelrath, Viktoria, et al.
Publicado: (2018)

Insights into IgM-mediated complement activation based on in situ structures of IgM-C1-C4b
por: Sharp, Thomas H., et al.
Publicado: (2019)

Editorial: Complement and Immunotherapeutics
por: Okrój, Marcin, et al.
Publicado: (2021)

Complement activation is required for IgM-mediated enhancement of the antibody response
Publicado: (1988)

IgM exacerbates glomerular disease progression in complement induced glomerulopathy
por: Panzer, Sarah E., et al.
Publicado: (2015)

Contribution of classical complement activation and IgM to the control of Rickettsia infection
por: Dahmani, Mustapha, et al.
Publicado: (2021)

Complement-Activating IgM Enhances the Humoral but Not the T Cell Immune Response in Mice
por: Ding, Zhoujie, et al.
Publicado: (2013)

Staphylococcus pseudintermedius Sbi paralogs inhibit complement and bind IgM, IgG Fc and Fab
por: Sewid, Alaa H., et al.
Publicado: (2019)

Advances in Immunotherapeutics in Pancreatic Ductal Adenocarcinoma
por: Chouari, Tarak, et al.
Publicado: (2023)

Dendrimer end-terminal motif-dependent evasion of human complement and complement activation through IgM hitchhiking
por: Wu, Lin-Ping, et al.
Publicado: (2021)

Three different pathways of IgM-antibody-dependent hemolysis are mainly regulated by complement
por: Bartolmäs, Thilo, et al.
Publicado: (2023)

IgM N-glycosylation correlates with COVID-19 severity and rate of complement deposition
por: Haslund-Gourley, Benjamin, et al.
Publicado: (2023)

Structural Model for Factor X Inhibition of IgM and Complement-Mediated Neutralization of Adenovirus
por: Wagner, Nicole, et al.
Publicado: (2023)

Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia
por: Dereani, Sara, et al.
Publicado: (2014)

Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenocarcinoma
por: He, Mengni, et al.
Publicado: (2020)

The Dual Role of a Polyvalent IgM/IgA-Enriched Immunoglobulin Preparation in Activating and Inhibiting the Complement System
por: Schmidt, Carolin, et al.
Publicado: (2021)

Circulating immune-complexes of IgG/IgM bound to B2-glycoprotein-I associated with complement consumption and thrombocytopenia in antiphospholipid syndrome
por: Naranjo, Laura, et al.
Publicado: (2022)

Reference Intervals for Serum Immunoglobulins IgG, IgA, IgM and Complements C3 and C4 in Iranian Healthy Children
por: Kardar, GA, et al.
Publicado: (2012)

The effect of complement on the ingestion of soluble antigen-antibody complexes and IgM aggregates by mouse peritoneal macrophages
Publicado: (1978)

Complement Receptors 1 and 2 in Murine Antibody Responses to IgM-Complexed and Uncomplexed Sheep Erythrocytes
por: Rutemark, Christian, et al.
Publicado: (2012)

A novel IgM–H-Ficolin complement pathway to attack allogenic cancer cells in vitro
por: Lei, Xiaoying, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_b9rv62apav528h1nd0e7cs70j6